Loading stock data…
Insight Molecular Diagnostics Inc (IMDX)
$4.27+0.14 (+3.39%)
Market ClosedLast close Sep 8
Insight Molecular Diagnostics Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Insight Molecular Diagnostics Inc. in the Healthcare sector is trading at $4.27 with a market capitalization of $177M. Wall Street consensus targets $8.25 (4 analysts), implying a +93.2% move over the next 12 months. The stock is currently 50% below its 52-week high of $8.51, remaining 18.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +93.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $32,000↓ | $1.14M↑ | $260,000↓ | $518,000↓ | $2.14M |
| Gross Profit | $15,000↓ | $496,000↑ | $139,000↓ | $350,000↓ | $1.32M |
| Operating Income | -$10.33M↓ | -$9.95M↓ | -$7.67M↓ | -$6.97M↓ | -$5.92M |
| Net Income | -$4.29M↑ | -$22.95M↓ | -$10.85M↓ | -$9.74M↓ | -$6.67M |
Peer Comparison
JNJUNHPFE
Fundamentals
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$177.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
447.49%
Volume
Today's trading volume
212,814
Recent News
Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript
FDA review nears completion as reimbursement rates support commercial launch.
Oncocyte Eyes Faster, Less Invasive Heart Transplant Rejection Testing
Insight Molecular Diagnostics discussed the potential use of donor-derived cell-free DNA testing in heart transplant surveillance during a virtual session featuring transplant cardiologist Dr. Max Liebo of Loyola University. Chief Executive Officer Josh Riggs said the company’s GraftAssureDx test i
Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary
Moby summary of Insight Molecular Diagnostics Inc.'s Q2 2026 earnings call
Oncocyte Q2 Earnings Call Highlights
Oncocyte (NASDAQ:IMDX) executives said they continue to target FDA marketing authorization for the GraftAssureDx kidney-transplant rejection test later this year, while preparing for a commercial launch and managing spending ahead of expected revenue growth. During the company’s second-quarter call
Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment
Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) is one of the high-growth micro-cap stocks to buy now. On June 11, Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) announced the online publication in the American Journal of Transplantation of new data demonstrating the statistical superiority of its flagship GraftAssure transplant rejection monitoring assay. The study showed that the novel GraftAssure […]